The Role of Antidepressants in the Management of Fibromyalgia Syndrome

@article{Huser2012TheRO,
  title={The Role of Antidepressants in the Management of Fibromyalgia Syndrome},
  author={Winfried H{\"a}user and Frederick Wolfe and Thomas R. T{\"o}lle and Nurcan {\"U}çeyler and Claudia Sommer},
  journal={CNS Drugs},
  year={2012},
  volume={26},
  pages={297-307}
}
AbstractBackground: The role of antidepressants in the management of fibromyalgia syndrome (FMS) still needs to be determined. Objective: The objective of this study was to provide a quantitative analysis (meta-analysis) of the efficacy and harms of antidepressants in the management of adult FMS patients. Data sources: The data sources used were the databases MEDLINE, SCOPUS and the Cochrane Central Register of Controlled Trials (until December 30, 2010), the reference lists of included… Expand

Paper Mentions

Interventional Clinical Trial
Fibromyalgia is serious chronic pain condition which is often accompanied by sleep disturbances, fatigue and disability and reduced quality of life. There is no cure and… Expand
ConditionsFibromyalgia
InterventionDrug
Review of pharmacological therapies in fibromyalgia syndrome
This review addresses the current status of drug therapy for the management of fibromyalgia syndrome (FMS) and is based on interdisciplinary FMS management guidelines, meta-analyses of drug trialExpand
[Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles].
TLDR
Amitriptyline and duloxetine are recommended in the case of comorbid depressive disorders or generalized anxiety disorder and pregabalin in the cases of generalized anxiety Disorder and off-label use of dulOxetine and preGabalin can be considered. Expand
An update on pharmacotherapy for the treatment of fibromyalgia
TLDR
None of the currently available drugs are fully effective against the whole spectrum of fibromyalgia symptoms, namely pain, fatigue, sleep disturbances and depression, among the most relevant symptoms. Expand
Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
TLDR
The quality of evidence was very low for each outcome and the risks of bias of the studies were assessed, and SSRIs did not statistically, or clinically, significantly reduce fatigue. Expand
Amitriptyline for the treatment of fibromyalgia: a comprehensive review
TLDR
Low doses of tricyclic antidepressant amitriptyline in low doses are effective for the treatment of fibromyalgia and, despite the limited quality of the data, they do not seem to be associated with relevant tolerability or safety issues. Expand
Controlled-release pregabalin in the treatment of fibromyalgia
TLDR
The efficacy and safety profiles of PGB-CR seem to be similar to those of the IR formulation, and the convenience of once-daily dosing potentially enhances patient compliance, however, the amount of evidence is not sufficient to draw any definite conclusions, and further studies of larger patient samples are needed. Expand
Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology
TLDR
Amitriptyline, Pregabalin and Duloxetine are used most commonly in FMS and though modestly effective, are useful adjunctive treatment to non-pharmaceutical measures. Expand
EULAR revised recommendations for the management of fibromyalgia
TLDR
These recommendations are underpinned by high-quality reviews and meta-analyses and propose research priorities clarifying who will benefit from specific interventions, their effect in combination and organisation of healthcare systems to optimise outcome. Expand
Fibromyalgia: a clinical review.
TLDR
Fibromyalgia may be considered as a discrete diagnosis or as a constellation of symptoms characterized by central nervous system pain amplification with concomitant fatigue, memory problems, and sleep and mood disturbances. Expand
A meta-analysis to determine the effect of pharmacological and non-pharmacological treatments on fibromyalgia symptoms comprising OMERACT-10 response criteria
TLDR
Indirect evidence indicates that it may be expected with the use of serotonin noradrenaline reuptake inhibitors (SNRIs), noradrene reuptakes inhibitors (NRIs), and multidisciplinary treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis.
TLDR
Antidepressant medications are associated with improvements in pain, depression, fatigue, sleep disturbances, and health-related quality of life in patients with FMS. Expand
Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials.
TLDR
There is strong evidence that multicomponents treatment has beneficial short-term effects on the key symptoms of FMS and strategies to maintain the benefits of multicomponent treatment in the long term need to be developed. Expand
Efficacy of hydrotherapy in fibromyalgia syndrome--a meta-analysis of randomized controlled clinical trials.
TLDR
There is moderate evidence that hydrotherapy has short-term beneficial effects on pain and HRQOL in FMS patients and there is a risk to over-estimate the effects of hydroTherapy due to methodological weaknesses of the studies and to small trials included in meta-analysis. Expand
Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials
TLDR
An aerobic exercise programme for FMS patients should consist of land-based or water-based exercises with slight to moderate intensity two or three times per week for at least 4 weeks, and continuing exercise was associated with positive outcomes at follow-up. Expand
EULAR evidence-based recommendations for the management of fibromyalgia syndrome
TLDR
Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus using a Delphi process. Expand
Adverse Events Attributable to Nocebo in Randomized Controlled Drug Trials in Fibromyalgia Syndrome and Painful Diabetic Peripheral Neuropathy: Systematic Review
TLDR
Nocebo effects substantially accounted for AEs in drug trials of FMS and DPN and Standards to assess and report AEs should be defined by regulatory agencies and strategies to minimize nocebos effects should be developed. Expand
Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.
TLDR
AMT cannot be regarded as the gold standard of FMS therapy with antidepressants because of the methodological limitations of its trials and there were no significant differences in acceptability of the three drugs. Expand
Systematic review: Placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy—magnitude and patient-related predictors
TLDR
The placebo response was higher in painful DPN than in FMS (P < .001), and the effects of Placebo achieved a substantial proportion of the benefits of drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy. Expand
Guidelines on the management of fibromyalgia syndrome – A systematic review
TLDR
Although there was some consistency in the recommendations regarding pharmacological treatments among the three guidelines, the APS and AWMF guidelines assigned higher ratings to CBT and multicomponent treatments, the inconsistencies across guidelines are likely attributable to the criteria used for study inclusion, weighting systems, and composition of the panels. Expand
Fibromyalgia syndrome: classification, diagnosis, and treatment.
TLDR
A stepwise treatment approach in which the patient and the physician decide jointly on the treatment options is recommended, and the most strongly recommended forms of treatment are aerobic exercise, amitriptyline, cognitive behavioral therapy, and spa therapy. Expand
...
1
2
3
4
5
...